Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

Jordan M. Estroff; Joseph Devlin; Lara Hoteit; Adnan Hassoune; Matthew D. Neal; Joshua B. Brown; Liling Lu; Shannon R. Kotch; Joshua P. Hazelton; Ashton B. Christian; Eric O. Yeates; Jeffry Nahmias; Lewis E. Jacobson; Jamie Williams; Kevin M. Schuster; Rick O’Connor; Gregory Semon; Angela D. Straughn; Daniel C. Cullinane; Tanya Egodage; Michelle Kincaid; A. Rollins; Richard Amdur; Babak Sarani

doi:10.1097/ta.0000000000004345

Abstract

Andexanet alfa (AA) is the only FDA-approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with four-factor prothrombin complex concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing noninferiority of PCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Estroff et al. (2024) studied this question.

synapsesocial.com/papers/68e6cbf0b6db643587649f46 https://doi.org/10.1097/ta.0000000000004345

View at Publisher

Ask AI

Bookmark

Share

Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

Abstract

Discussion

Cite This Study

Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading